386 related articles for article (PubMed ID: 16145529)
1. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas.
Rachinger W; Goetz C; Pöpperl G; Gildehaus FJ; Kreth FW; Holtmannspötter M; Herms J; Koch W; Tatsch K; Tonn JC
Neurosurgery; 2005 Sep; 57(3):505-11; discussion 505-11. PubMed ID: 16145529
[TBL] [Abstract][Full Text] [Related]
2. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy.
Floeth FW; Pauleit D; Wittsack HJ; Langen KJ; Reifenberger G; Hamacher K; Messing-Jünger M; Zilles K; Weber F; Stummer W; Steiger HJ; Woebker G; Müller HW; Coenen H; Sabel M
J Neurosurg; 2005 Feb; 102(2):318-27. PubMed ID: 15739561
[TBL] [Abstract][Full Text] [Related]
3. Comparison of O-(2-
Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
World Neurosurg; 2018 May; 113():e727-e737. PubMed ID: 29510293
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
5. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.
Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032
[TBL] [Abstract][Full Text] [Related]
6. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
7. Potential for differentiation of glioma recurrence from radionecrosis using integrated
Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
[TBL] [Abstract][Full Text] [Related]
8. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.
Pauleit D; Floeth F; Hamacher K; Riemenschneider MJ; Reifenberger G; Müller HW; Zilles K; Coenen HH; Langen KJ
Brain; 2005 Mar; 128(Pt 3):678-87. PubMed ID: 15689365
[TBL] [Abstract][Full Text] [Related]
9. 18F-FET PET differentiation of ring-enhancing brain lesions.
Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI.
Pyka T; Hiob D; Preibisch C; Gempt J; Wiestler B; Schlegel J; Straube C; Zimmer C
Eur J Radiol; 2018 Jun; 103():32-37. PubMed ID: 29803382
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.
Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ
J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243
[TBL] [Abstract][Full Text] [Related]
13. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.
Floeth FW; Pauleit D; Sabel M; Stoffels G; Reifenberger G; Riemenschneider MJ; Jansen P; Coenen HH; Steiger HJ; Langen KJ
J Nucl Med; 2007 Apr; 48(4):519-27. PubMed ID: 17401087
[TBL] [Abstract][Full Text] [Related]
15. Multimodal imaging in cerebral gliomas and its neuropathological correlation.
Gempt J; Soehngen E; Förster S; Ryang YM; Schlegel J; Zimmer C; Meyer B; Ringel F; Grams AE; Förschler A
Eur J Radiol; 2014 May; 83(5):829-34. PubMed ID: 24629350
[TBL] [Abstract][Full Text] [Related]
16. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
[TBL] [Abstract][Full Text] [Related]
17. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
[TBL] [Abstract][Full Text] [Related]
18. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
19. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
Mehrkens JH; Pöpperl G; Rachinger W; Herms J; Seelos K; Tatsch K; Tonn JC; Kreth FW
J Neurooncol; 2008 May; 88(1):27-35. PubMed ID: 18217207
[TBL] [Abstract][Full Text] [Related]
20. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
